查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611113

硬皮症治疗市场规模、份额和趋势分析报告：按药物类别、适应症、地区和细分市场预测，2025-2030 年

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格

硬皮症治疗市场成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球硬皮症治疗市场规模将达到34.4亿美元，2025年至2030年复合年增长率为5.0%。市场成长是由各种标籤仿单标示外治疗的可用性所推动的，包括小分子疗法，包括品牌药、学名药和非处方药。

由于多种适应症和药物类别的混合，市场被多个参与企业分割。罗氏在生技药品免疫抑制剂方面拥有压倒性的市场份额，包括Actemra/RoActemra、Cellcept和Rituxan。辉瑞（Pfizer）和礼来（Eli Lilly）是该市场的主要企业。包括勃林格殷格翰、Corbus Pharmaceuticals 和 Fibrocell 在内的新参与企业预计将在预测期内略微抢占该市场现有企业的份额。

硬皮症治疗市场正处于发展阶段。额外的适应症核准是市场参与企业最常见的策略之一。例如，拜耳公司的利奥西呱（riociguat）先前用于治疗 PAH，目前正处于临床试验中，用于治疗与 SSc 相关的指部溃疡。其他製药公司也在效仿，因为这种策略对製药业有利，使他们能够抵消高昂的开发成本，并从已经开发并上市的单一分子中获得更大的利润。

硬皮症治疗市场报告亮点

  • 2024 年，免疫抑制剂市场占据最大份额，为 27.4%，并且可能在整个预测期内保持其主导地位。
  • 由于与此类药物相关的有利报销方案，对免疫抑制剂的高度偏好支持了市场占有率的主导地位。
  • 系统性硬皮症适应症占据主要市场占有率，并且由于高成本免疫抑制剂的使用，预计将进一步扩大。
  • 2024年，美国市场将占据北美硬皮症治疗市场90.6%的份额。硬皮症治疗市场的持续成长得益于预期的适应症扩大和First-in-Class疗法的推出，以及孤儿药报销的进展。
  • 主要原因是大量使用学名药和生物相似药来进行硬皮症的仿单标示外治疗。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章硬皮症治疗市场变数、趋势、范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章硬皮症治疗市场：药物类别的商业分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年按药物类别分類的市场规模、预测与趋势分析
  • 免疫抑制剂
  • 磷酸二酯酶5抑制剂-PHA
  • 内皮素受体拮抗剂
  • 前列腺环素类似物
  • 钙离子通道阻断剂
  • 止痛药
  • 钙离子通道阻断剂
  • 其他的

第五章硬皮症治疗市场：适应症的商业分析

  • 2024年及2030年指示市场占有率
  • 指示细分仪表板
  • 2018-2030 年市场规模、预测与趋势分析（依指标）
  • 系统性硬皮症
  • 局部硬皮症

第六章硬皮症治疗市场：按药物类别分類的区域估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • F. Hoffman La-Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Emerald Health Pharmaceuticals
    • Sanofi
    • Cytori Therapeutics Inc.
    • Chemomab
    • Corbus Pharmaceuticals Holdings, Inc.
    • Calliditas Therapeutics AB
Product Code: GVR-3-68038-219-8

Scleroderma Therapeutics Market Growth & Trends:

The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company's share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Scleroderma Therapeutics Market Report Highlights:

  • The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years
  • High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
  • Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
  • The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
  • Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Scleroderma Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Scleroderma Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Immunosuppressors
    • 4.4.1. Immunosuppressors Market, 2018 - 2030 (USD Million)
  • 4.5. Phosphodiesterase 5 inhibitors - PHA
    • 4.5.1. Phosphodiesterase 5 inhibitors - PHA Market, 2018 - 2030 (USD Million)
  • 4.6. Endothelin Receptor Antagonists
    • 4.6.1. Endothelin Receptor Antagonists Market, 2018 - 2030 (USD Million)
  • 4.7. Prostacyclin Analogues
    • 4.7.1. Prostacyclin Analogues Market, 2018 - 2030 (USD Million)
  • 4.8. Calcium Channel Blockers
    • 4.8.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
  • 4.9. Analgesics
    • 4.9.1. Analgesics Market, 2018 - 2030 (USD Million)
  • 4.10. Calcium Channel Blockers
    • 4.10.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Scleroderma Therapeutics Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Systemic Scleroderma
    • 5.4.1. Systemic Scleroderma Market, 2018 - 2030 (USD Million)
    • 5.4.2. Morphea
      • 5.4.2.1. Morphea Market, 2018 - 2030 (USD Million)
    • 5.4.3. Linear
      • 5.4.3.1. Linear Market, 2018 - 2030 (USD Million)
  • 5.5. Localized Scleroderma
    • 5.5.1. Localized Scleroderma Market, 2018 - 2030 (USD Million)
    • 5.5.2. Diffuse Systemic Sclerosis
      • 5.5.2.1. Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
    • 5.5.3. Limited Cutaneous Systemic Sclerosis Syndrome
      • 5.5.3.1. Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)

Chapter 6. Scleroderma Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class and Indication

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Australia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Scleroderma therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. F. Hoffman La-Roche Ltd
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bristol-Myers Squibb Company
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bayer AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Boehringer Ingelheim International GmbH
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Emerald Health Pharmaceuticals
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sanofi
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Cytori Therapeutics Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Chemomab
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Corbus Pharmaceuticals Holdings, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Calliditas Therapeutics AB
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global scleroderma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 North America scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 9 U.S. scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 U.S. scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Mexico scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 UK scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Germany scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Italy scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Italy scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Spain scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Spain scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Denmark scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Denmark scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Sweden scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Sweden scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Norway scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Norway scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Japan scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Japan scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 39 China scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 China scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 41 India scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 India scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Australia scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Australia scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 45 South Korea scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 South Korea scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Thailand scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Thailand scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Latin America scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Latin America scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Brazil scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Brazil scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Argentina scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Argentina scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Scleroderma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Africa scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 South Africa scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 63 UAE scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 UAE scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Kuwait scleroderma therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait scleroderma therapeutics market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Scleroderma therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market snapshot
  • Fig. 8 Drug class and indication outlook (USD Million)
  • Fig. 9 Competitive landscape
  • Fig. 10 Scleroderma therapeutics market dynamics
  • Fig. 11 Scleroderma therapeutics market: Porter's five forces analysis
  • Fig. 12 Scleroderma therapeutics market: PESTLE analysis
  • Fig. 13 Scleroderma therapeutics market: Drug class segment dashboard
  • Fig. 14 Scleroderma therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 15 Immunosuppressors market, 2018 - 2030 (USD Million)
  • Fig. 16 Phosphodiesterase 5 inhibitors - PHA market, 2018 - 2030 (USD Million)
  • Fig. 17 Endothelin receptor antagonists market, 2018 - 2030 (USD Million)
  • Fig. 18 Prostacyclin analogues market, 2018 - 2030 (USD Million)
  • Fig. 19 Calcium channel blockers market, 2018 - 2030 (USD Million)
  • Fig. 20 Analgesics market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Scleroderma therapeutics market: Indication segment dashboard
  • Fig. 23 Scleroderma therapeutics market: Indication market share analysis, 2024 & 2030
  • Fig. 24 Systemic scleroderma market, 2018 - 2030 (USD Million)
  • Fig. 25 Morphea market, 2018 - 2030 (USD Million)
  • Fig. 26 Linear market, 2018 - 2030 (USD Million)
  • Fig. 27 Localized scleroderma market, 2018 - 2030 (USD Million)
  • Fig. 28 Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 29 Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)
  • Fig. 30 Scleroderma therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway country dynamics
  • Fig. 56 Norway scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait scleroderma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework